Long-Term Effectiveness And Safety Of CP-690,550 For The Treatment Of Rheumatoid Arthritis

A Long-term, Open-label Follow-up Study Of Tofacitinib (Cp-690,550) For Treatment Of Rheumatoid Arthritis

The purpose of this study is to determine the long-term effectiveness and safety of CP-690,550 for the treatment of rheumatoid arthritis. Subjects are eligible for this study only after participating in another "qualifying" study of CP-690,550

A sub-study will be conducted within the A3921024 study, this study will evaluate the immune response to pneumococcal and influenza vaccines in patients receiving CP-690,550

Study Overview

• Status: Completed
• Conditions: Arthritis, Rheumatoid
• Intervention / Treatment: Drug: CP-690,550; Drug: CP-690,550

• Study Type: Interventional
• Enrollment (Actual): 4488
• Phase: Phase 3

Contacts and Locations

Study Locations

• Argentina
  • Buenos Aires, Argentina, C1015ABO
    • OMI - Organización Médica de Investigación
  • Buenos Aires, Argentina, C1034ACO
    • Saint Dennis Medical Group S.A.
  • Buenos Aires, Argentina, C1428DZF
    • Consultorios Reumatológicos Pampa
  • Buenos Aires, Argentina, 1419AHN
    • Hospital Sirio Libanes
  • Buenos Aires, Argentina, C1419AHN
    • Hospital Sirio Libanes
  • Caba
    • Buenos Aires, Caba, Argentina, C1015ABO
      • OMI- Organización Médica de Investigación
    • Buenos Aires, Caba, Argentina, C1114AAH
      • Centro de Investigaciones Reumatologicas y Osteologicas -CIRO
• Australia
  • St Leonards, Australia, NSW2065
    • Royal North Shore Hospital
  • New South Wales
    • Kogarah, New South Wales, Australia, 2217
      • Optimus Clinical Research Pty. Ltd.
  • Queensland
    • Cairns, Queensland, Australia, 4870
      • Rheumatology Research
    • Maroochydore, Queensland, Australia, 4558
      • Rheumatology Research Unit Sunshine Coast
  • South Australia
    • Woodville, South Australia, Australia, 5011
      • Queen Elizabeth Hospital, Department of Rheumatology
  • Victoria
    • Malvern East, Victoria, Australia, 3145
      • Emeritus Research
  • Western Australia
    • Perth, Western Australia, Australia, WA 6000
      • Goatcher Clinical Research Unit
• Austria
  • Wien, Austria, A-1090
    • Medizinische Universitaet Wien / AKH
  • Wien, Austria, A-1100
    • Rheuma-Ordination Favoriten
  • Wien, Austria, A-1100
    • Sozialmedizinisches Zentrum Sued - Kaiser Franz Josef Spital
• Belgium
  • Kortrijk, Belgium, 8500
    • AZ Groeninge
  • Liège, Belgium, 4020
    • Centre Hospitalier Universitaire de Liège
  • Oost-vlaanderen
    • Gent, Oost-vlaanderen, Belgium, 9000
      • Universitair Ziekenhuis Gent - Reumatologie
• Bosnia and Herzegovina
  • Sarajevo, Bosnia and Herzegovina, 71000
    • University Clinical Center Sarajevo
• Brazil
  • Sao Paulo, Brazil, 04266-010
    • CEPIC - Centro Paulista de Investigacao Clinica e Servicos Medicos Ltda
  • GO
    • Goiania, GO, Brazil, 74110-120
      • CIP - Centro Internacional de Pesquisa
  • PR
    • Curitiba, PR, Brazil, 80060-240
      • Centro de Estudos em Terapias Inovadoras
  • Paraná
    • Curitiba, Paraná, Brazil, 80030-110
      • Centro de Estudos em Terapias Inovadoras
  • RJ
    • Rio de Janeiro, RJ, Brazil, 22271-100
      • CCBR Brasil Centro de Pesquisas e Analises Clinicas Ltda
  • RS
    • Porto Alegre, RS, Brazil, 90035-903
      • Hospital de Clinicas de Porto Alegre
    • Porto Alegre, RS, Brazil, 90610-000
      • Hospital Sao Lucas Da Pucrs
  • SP
    • Sao Paulo, SP, Brazil, 01323-903
      • Hospital Alemao Oswaldo Cruz
    • Sao Paulo, SP, Brazil, 05403-010
      • Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo (HC-FMUSP)
    • Sao Paulo, SP, Brazil, 05437-010
      • IMA Brasil -Instituto de Pesquisa Clinica e Medicina Avancada
• Bulgaria
  • Pleven, Bulgaria, 5800
    • Revmatologichen kabinet, DKTs Sveti Pantaleimon OOD
  • Plovdiv, Bulgaria, 4000
    • Revmatologichno Otdelenie, MBAL - Plovdiv
  • Plovdiv, Bulgaria, 4002
    • UMBAL Kaspela Plovdiv
  • Sevlievo, Bulgaria, 5400
    • MBAL Akta Medika OOD
  • Sofia, Bulgaria, 1606
    • Clinic of Cardiology and Rheumatology Military Medical Academy
  • Sofia, Bulgaria, 1612
    • Clinic of Rheumatology Multiprofile Hospital for Active Treatment Sveti Ivan Rilski
  • Sofia, Bulgaria, 1612
    • MBAL Sveti Ivan Rilski Sofia
  • Sofia, Bulgaria, 1709
    • DKTs "Sveta Anna" Sofia, Konsultativen kabinet po Revmatologia
  • Sofia, Bulgaria, 1709
    • DKTs "Sveta Anna", Sofia / Diagnostic Consultative Center "Sveta Anna"
  • Veliko Tarnovo, Bulgaria, 5000
    • MOBAL "D-r Stefan Cherkezov" AD,
• Canada
  • Quebec, Canada, G1W4R4
    • Centre de Recherche Saint-Louis
  • Quebec, Canada, G1V 3M7
    • Groupe De Recherche En Rhumatologie Et Maladies Osseuses Inc.
  • Alberta
    • Edmonton, Alberta, Canada, T5M 0H4
      • Rheumatology Research Associates Ltd.
  • British Columbia
    • Vancouver, British Columbia, Canada, V5Z 1L7
      • Dr. Alice Klinkhoff, Inc.
    • Victoria, British Columbia, Canada, V8V 3P9
      • PerCuro Clinical Research Limited
  • Manitoba
    • Winnipeg, Manitoba, Canada, R3A 1M3
      • Manitoba Clinic
  • Newfoundland and Labrador
    • St. John's, Newfoundland and Labrador, Canada, A1A 5E8
      • Nexus Clinical Research
  • Ontario
    • Hamilton, Ontario, Canada, L8N 2B6
      • Cividino Medicine Professional Corporation
    • Hamilton, Ontario, Canada, L8N 1Y2
      • Dr. William G. Bensen Medicine Professional Corporation
    • Hamilton, Ontario, Canada, L8N 1Y2
      • Office of Dr. Fernando Bianchi
    • Kitchener, Ontario, Canada, N2M 5N6
      • KW Musculoskeletal Research Inc.
    • London, Ontario, Canada, N6A 4V2
      • St Joseph's Health Centre
    • Missisauga, Ontario, Canada, L5M 2V8
      • Credit Valley Rheumatology
    • Newmarket, Ontario, Canada, L3Y 3R7
      • The Arthritis Program Research Group Inc.
    • Oakville, Ontario, Canada, L6M 4J2
      • Rheumatology and Osteoporosis Clinic
    • Ottawa, Ontario, Canada, K1H 1A2
      • Rheumatology Research Associates
    • St. Catharines, Ontario, Canada, L2N 7E4
      • Niagara Peninsula Arthritis Centre
    • Windsor, Ontario, Canada, N8X 5A6
      • Clinical Research and Arthritis Centre
  • Quebec
    • Montreal, Quebec, Canada, H2L 1S6
      • Institut de Rhumatologie de Montreal
    • Pointe Claire, Quebec, Canada, H9R 3J1
      • West Island Rheumatology Research Associates
    • Trois-Rivieres, Quebec, Canada, G8Z 1Y2
      • Centre de Recherche Musculo-Squelettique
  • Saskatchewan
    • Saskatoon, Saskatchewan, Canada, S7N 0W8
      • Arthritis Research Center, Royal University Hospital
• Chile
  • Rancagua, Chile, 2841959
    • Hospital Regional de Rancagua
  • Santiago, Chile, 7530206
    • Clinica Santa Maria
  • Vina Del Mar, V Region, Chile, 2520997
    • Estudios Clinicos V Region
  • IX Region
    • Temuco, IX Region, Chile, 4790928
      • Consulta Privada Dra. Lucia Ponce
  • RM
    • Santiago, RM, Chile, 7501126
      • Centro de Estudios Reumatologicos
    • Santiago, RM, Chile, 7510186
      • Consulta Privada Dra. Marta Aliste
  • Region Metropolitana
    • Santiago, Region Metropolitana, Chile, 8360156
      • Centro de Diagnostico y Tratamiento Hospital San Borja Arriaran
  • Region XIV
    • Valdivia, Region XIV, Chile, 5090145
      • Hospital Base Valdivia, Policlinico de Reumatologia
  • Santiago, RM
    • Providencia, Santiago, RM, Chile, 7530206
      • Clínica Santa María, Sección Reumatología
• China
  • Beijing, China, 100853
    • PLA General Hospital
  • Beijing, China, 100044
    • Peking University People's Hospital/Rheumatology and Immunology Department
  • Chengdu, China, 610041
    • Si Chuan Huaxi Hospital
  • Hangzhou, China, 310009
    • The Second Affiliated hospital of Zhejiang University school of medicine
  • Hefei, China, 230001
    • Anhui Province Hospital
  • Hefei, China, 230022
    • An Hui Medical University 1st Hospital
  • Nanjing, China, 210029
    • Jiangsu Province Hospital
  • Shanghai, China, 200433
    • Shanghai Changhai Hospital
  • Shanghai, China, 200001
    • Rheumatology and Immunology Dept., Renji Hospital Shanghai Jiao Tong University School of Medicine
  • Suzhou, China, 215006
    • The First Affiliated Hospital of Soochow University
  • Tianjin, China, 300052
    • "Department of Infectious Diseases & Immunology
  • Beijing
    • Beijing, Beijing, China, 100020
      • Beijing Chaoyang Hospital, Capital University of Medical Science
  • Guangdong
    • Guangzhou, Guangdong, China, 510630
      • The third affiliated hospital of Sun Yat-Sen University
    • Guangzhou, Guangdong, China, 510260
      • The Second Affiliated Hospital of Guangzhou Medical University
  • Hubei
    • Wuhan, Hubei, China, 430030
      • Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology
  • Hunan
    • Changsha, Hunan, China, 410008
      • Xiangya Hospital of Centre-South University
  • Shaanxi
    • Xi'an, Shaanxi, China, 710032
      • Xijing Hospital, The Fourth Military Medical University
  • Shandong
    • Jinan, Shandong, China, 250012
      • Qilu Hospital of Shandong University
    • Qingdao, Shandong, China, 266011
      • Qingdao Municipal Hospital
  • Shanghai
    • Shanghai, Shanghai, China, 200003
      • Shanghai Changzheng Hospital
• Colombia
  • Atlantico
    • Barranquilla, Atlantico, Colombia
      • Centro de Reumatologia y Ortopedia S.A.S.
  • Cundinamarca
    • Bogota D.C., Cundinamarca, Colombia
      • Riesgo de Fractura S.A.
    • Bogota, D.C., Cundinamarca, Colombia
      • Centro de Investigacion en Reumatologia y Especialidades Medicas S.A.S CIREEM S.A.S
  • Santander
    • Bucaramanga, Santander, Colombia, 680003
      • Servimed S.A.S.
• Costa Rica
  • Cartago, Costa Rica
    • Centro de Reumatología y Osteoporosis, Cartago
  • San Jose, Costa Rica, 00000
    • Hospital CIMA San Jose
  • San Jose, Costa Rica
    • Hospital CIMA San Jose
  • San Jose, Costa Rica
    • Oficina Privada Del Colegio deMedicos
• Croatia
  • Osijek, Croatia, 31000
    • University Hospital Center Osijek
  • Split, Croatia, 21000
    • University Hospital Split, Department for Internal Medicine, Division of Clinical Rheumatology
  • Zagreb, Croatia, 10000
    • University Hospital Center Zagreb
  • Zagreb, Croatia, 10 000
    • Clinical Hospital "Sveti Duh"
  • Zagreb, Croatia, 10000
    • University Hospital Center "Zagreb"
• Czechia
  • Brno, Czechia, 656 91
    • Fakultni nemocnice u sv. Anny v Brne
  • Brno, Czechia, 615 00
    • Revmacentrum MUDr. Mostera, s.r.o.
  • Brno, Czechia, 61300
    • X-MEDICA s.r.o.
  • Brno, Czechia, 625 00
    • Fakultni nemocnice Brno, Interni hematoonkologicka klinika
  • Ceska Lipa, Czechia, 470 01
    • HESTE s.r.o. Revmatologie
  • Ceske Budejovice, Czechia, 370 01
    • MEDIPONT Plus sro
  • Hlucin, Czechia, 748 01
    • L.K.N. Arthrocentrum, s.r.o.
  • Hostivice, Czechia, 253 01
    • ARTMEDI UPD s r.o
  • Hradec Kralove, Czechia, 50005
    • Fakultni nemocnice Hradec Kralove
  • Ostrava, Czechia, 70800
    • Revmatologicka ambulance
  • Pardubice, Czechia, 530 02
    • ARTHROMED, s. r. o. Revmatologicka ambulance
  • Praha 11 - Chodov, Czechia, 148 00
    • Affidea Praha, s.r.o.
  • Praha 2, Czechia, 12850
    • Revmatologicky ustav
  • Praha 4, Czechia, 140 00
    • Revmatologicka ambulance
  • Praha 4, Czechia, 14000
    • Revmatologicka ambulance
  • Praha 4, Czechia, 140 59
    • Fakultni Thomayerova nemocnice s poliklinikou
  • Praha 4, Czechia, 14000
    • Nuselska poliklinika RTG
  • Zlin, Czechia, 760 01
    • PV-MEDICAL s.r.o.
  • Zlin, Czechia, 760 01
    • Nemocnice Atlas, a.s.
• Denmark
  • Frederiksberg, Denmark, 2000
    • Frederiksberg Hospital
• Dominican Republic
  • Santo Domingo, Dominican Republic, 10119
    • Hospital Central de las Fuerzas Armadas
• Finland
  • Helsinki, Finland, 00120
    • Helsingin Reumakeskus Oy
  • Hyvinkaa, Finland, 05800
    • Kiljavan Lääketutkimus Oy
  • Tampere, Finland, 33520
    • TAYS/Reumakeskus/Finn-Medi 1
• France
  • Amiens, France, 80000
    • Hopital Nord
  • Orleans, France, 45000
    • *CHR Hopital Porte Madeleine IPROS
  • Orleans, France, 45032
    • CHR ORLEANS - Service IPROS
  • Paris, France, 75012
    • Hôpital Saint-Antoine
  • Paris, France, 75014
    • Hopital Cochin
• Germany
  • Aachen, Germany, 52064
    • Privat-Praxis
  • Berlin, Germany, 10117
    • Charite Campus Mitte, Medizinische Klinik mit Schwerpunkt Rheumatologie und Klinische Immunologie
  • Berlin, Germany, 14059
    • Schlosspark-Klinik Innere Medizin II, Rheumatologie
  • Berlin, Germany, 14163
    • Ambulantes Rheumazentrum Dr Soerensen
  • Dresden, Germany, 01067
    • Krankenhaus Friedrichstadt, I. Medizinische Klinik
  • Erlangen, Germany, 91054
    • Studienambulanz Universitaetsklinikum Erlangen Medizinische Klinik 3
  • Frankfurt am Main, Germany, 60590
    • J.W.-Goethe-Universitaetsklinik, Medizinische Klinik II, Abteilung fuer Rheumatologie
  • Halle, Germany, 06108
    • Schwerpunktpraxis Rheumatologie
  • Hamburg, Germany, 22081
    • Schoen Klinik Hamburg-Eilbek
  • Herne, Germany, 44649
    • Rheumazentrum Ruhrgebiet
  • Koeln, Germany, 50937
    • Universitaetsklinikum Koeln Klinik I fuer Innere Medizin, Haus 16, 1. OG, Raum 1.008
  • Leipzig, Germany, 04103
    • Universitaetsklinikum Leipzig
  • Leipzig, Germany, 04103
    • Universitaetsklinik Leipzig, Klinik fur Gastroenterologie und Rheumatologie, Sektion Rheumatologie
  • Muenchen, Germany, 80336
    • Klinikum der Universitaet Muenchen, Campus Innenstadt, Rheuma-Einheit
  • Nuernberg, Germany, 90429
    • Arztpraxis, Internist - Rheumatologie
  • Ratingen, Germany, 40882
    • Rheumaforschung- Studienambulanz
  • Rheine, Germany, 48431
    • Schwerpunktpraxis fuer Rheumatologie
  • Wuerzburg, Germany, 97080
    • Universitaetsklinikum Wuerzburg
• Greece
  • Thessaloniki, Greece, 54636
    • General Hospital Euromedica "KYANOUS STAVROS"
  • Thessaloniki, Greece, 56429
    • 424 General Army Hospital
• Hungary
  • Balatonfured, Hungary, 8230
    • Drug Research Center Kft
  • Budapest, Hungary, 1027
    • Revita Reumatologiai Rendelo
  • Budapest, Hungary, 1023
    • Orszagos Reumatologiai es Fizioterapias Intezet
  • Budapest, Hungary, H-1036
    • Synexus Magyarorszag Kft.
  • Szolnok, Hungary, 5000
    • MAV Korhaz es Rendelointezet, Reumatologiai szakrendeles
• India
  • Andhra Pradesh
    • Hyderabad, Andhra Pradesh, India, 500 004
      • Mahavir Hospital & Research Center
  • Gujarat
    • Ahmedabad, Gujarat, India, 380009
      • Rheumatic Diseases Clinic
    • Ahmedabad, Gujarat, India, 380015
      • Shalby Hospitals
  • Karnataka
    • Bangalore, Karnataka, India, 560 054
      • Shirdi Sai Hospital
    • Bangalore, Karnataka, India, 560 003
      • ChanRe Rheumatology And Immunology Center And Research
    • Bangalore, Karnataka, India, 560 034
      • St. John's Medical College and Hospital.
    • Bangalore, Karnataka, India, 560 079
      • Chanre Rheumatology & Immunology Center & Research
  • Maharashtra
    • Pune, Maharashtra, India, 411001
      • Jehangir Clinical Development Centre Pvt. Ltd.
    • Pune, Maharashtra, India, 411 001
      • Arthritis Research and Care Foundation Centre for Rheumatic Diseases
  • Telangana
    • Secunderabad, Telangana, India, 500 003
      • Krishna Institute of medical sciences Ltd
• Ireland
  • Dublin
    • Elm Park, Dublin, Ireland
      • St. Vincent's University Hospital
• Italy
  • Genova, Italy, 16132
    • U.O. Clinica Reumatologica
  • FI
    • Firenze, FI, Italy, 50139
      • A.O.U. Careggi - SOD Medicina Interna 1 e Reumatologia
• Korea, Republic of
  • Busan, Korea, Republic of, 49201
    • Dong-A University Hospital
  • Daegu, Korea, Republic of, 42472
    • Daegu Catholic University Medical Center
  • Gwangju, Korea, Republic of, 61469
    • Chonnam National University Hospital
  • Seoul, Korea, Republic of, 03080
    • Seoul National University Hospital
  • Seoul, Korea, Republic of, 05030
    • Konkuk University Medical Center
  • Seoul, Korea, Republic of, 05505
    • Asan Medical Center
  • Seoul, Korea, Republic of, 04763
    • Hanyang University Hospital
  • Seoul, Korea, Republic of, 03722
    • Yonsei University Health System
  • Seoul, Korea, Republic of, 05505
    • Asan Medical Center-University of Ulsan College of Medicine
  • Seoul, Korea, Republic of, 06273
    • Gangnam Severance Hospital-Yonsei University Health System
  • Seoul, Korea, Republic of, 06591
    • Seoul St. Mary's Hospital-The Catholic University of Korea
  • Seoul,, Korea, Republic of, 06273
    • Gangnam Severance Hospital
  • Incheon
    • Jung-gu, Incheon, Korea, Republic of, 22332
      • Inha University Hospital
  • Republic OF Korea
    • Daejeon, Republic OF Korea, Korea, Republic of, 35233
      • Eulji University Hospital
• Malaysia
  • Negeri Sembilan
    • Seremban, Negeri Sembilan, Malaysia, 70300
      • Hospital Tuanku Ja'afar
  • Sabah
    • Kota Kinabalu, Sabah, Malaysia, 88586
      • Queen Elizabeth Hospital
  • Sarawak
    • Kuching, Sarawak, Malaysia, 93586
      • Sarawak General Hospital
  • Selangor
    • Batu Caves, Selangor, Malaysia, 68100
      • Hospital Selayang
    • Petaling Jaya, Selangor, Malaysia, 46150
      • Sunway Medical Centre
    • Subang Jaya, Selangor, Malaysia, 47500
      • Subang Jaya Medical Centre
  • Wilayah Persekutuan
    • Putrajaya, Wilayah Persekutuan, Malaysia, 62250
      • Hospital Putrajaya, Dept. of Medicine
• Mexico
  • Chihuahua, Mexico, 31000
    • Investigacion y Biomedica de Chihuahua, SC
  • Mexico City, Mexico, 14080
    • Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran
  • Mexico, D.F., Mexico, 11850
    • Hospital Angeles Mocel
  • Queretaro, Mexico, 76178
    • Centro Reumatologico Queretaro
  • San Luis Potosi, Mexico, 78213
    • Centro de Alta Especialidad en Reumatologia e Investigacion del Potosi, S.C.
  • San Luis Potosi, Mexico, 78240
    • Hospital Central Dr Ignacio Morones Prieto Unidad Regional de Reumatologia y Osteoporosis
  • BAJA California Norte
    • Tijuana, BAJA California Norte, Mexico, 22010
      • Centro de Investigación del Noroeste
  • Coahuila
    • Torreon, Coahuila, Mexico, 27000
      • Unidad de Enfermedades Reumaticas y Cronico Degenerativas SC
  • DF
    • Mexico, DF, Mexico, 10700
      • Hospital Ángeles del Pedregal
  • Estado DE Mexico
    • Metepec, Estado DE Mexico, Mexico, 52140
      • Centro Medico Toluca
  • Jalisco
    • Guadalajara, Jalisco, Mexico, 44160
      • Centro Integral en Reumatologia, SA de CV
    • Guadalajara, Jalisco, Mexico, 44620
      • Unidad de Investigacion en Enfermedades Cronico Degenerativas
  • Mexico D.F.
    • Coyoacan, Mexico D.F., Mexico, 04030
      • Centro de Investigacion Clinica Especializada, SC
  • Michoacan
    • Morelia, Michoacan, Mexico, 58070
      • Centro de Investigacion Clinica de Morelia
    • Morelia, Michoacan, Mexico, 58249
      • Clinica de Enfermedades Cronicas y Procedimientos Especiales SC
  • Morelos
    • Cuernavaca, Morelos, Mexico, 62170
      • Fundacion El Hospitalito
  • Nuevo LEON
    • Monterrey, Nuevo LEON, Mexico, 64020
      • Hospital Universitario Doctor José Eleuterio Gonzalez
  • Yucatan
    • Merida, Yucatan, Mexico, 97000
      • Unidad Reumatologica Las Americas SCP
• New Zealand
  • Christchurch, New Zealand, 8022
    • The Canterbury Geriatric Medical Research Trust, c/- The Princess Margaret Hospital
  • Hamilton, New Zealand, 3240
    • Waikato Hospital, Rheumatology
  • Timaru, New Zealand, 7910
    • Clinical Trials Unit, Timaru Hospital
• Peru
  • Callao, Peru, C-02
    • Hospital Nacional IV Alberto Sabogal Sologuren
  • Lima, Peru, L-27
    • Centro Medico Corpac/Investigaciones en Reumatologia
  • Lima, Peru, L-27
    • Instituto Peruano del Hueso y la Articulacion SAC-Privado-Lima/Centro de Investigacion IPHAR
• Philippines
  • Cebu City, Philippines, 6000
    • Chong Hua Hospital
  • Davao City, Philippines, 8000
    • Southern Philippine Medical Center
  • Las Piñas City, Philippines, 1742
    • University of Perpetual Help Rizal Dalta Medical Center
  • Manila, Philippines, 1008
    • University of Santo Tomas Hospital
  • Batangas
    • Lipa City, Batangas, Philippines, 4217
      • Mary Mediatrix Medical Center
  • Cavite
    • Dasmarinas, Cavite, Philippines, 4114
      • De La Salle University Health Sciences Campus Clinical Epidemiology Unit
  • Pampanga
    • Angeles City, Pampanga, Philippines, 2009
      • Angeles University Foundation Medical Center
• Poland
  • Bialystok, Poland, 15-879
    • ClinicMed Badurski i Wspolnicy Spolka Jawna
  • Bialystok, Poland, 15-351
    • "Zdrowie Osteo-Medic" s.c. Lidia i Artur Racewicz, Agnieszka i Jerzy Supronik
  • Cieszyn, Poland, 43400
    • NSZOZ Medicus II
  • Koscian, Poland, 64-000
    • Szpital im. Teodora Dunina
  • Krakow, Poland, 31-501
    • Krakowskie Centrum Medyczne NZOZ
  • Poznan, Poland, 60-773
    • Centrum Badan Klinicznych S.C. Wieslawa Porawska, Lukasz Porawski
  • Sopot, Poland, 81-759
    • Wojewodzki Zespol Reumatologiczny im. dr Jadwigi Titz-Kosko
  • Torun, Poland, 87-100
    • NZOZ "Nasz Lekarz"
  • Warszawa, Poland, 01-192
    • Synexus Polska Sp. z o.o. Oddzial w Warszawie
  • Warszawa, Poland, 02-118
    • Rheuma-Medicus - Specjalistyczne Centrum Reumatologii i Osteoporozy
  • Wroclaw, Poland, 50-088
    • SYNEXUS Polska Sp. z.o.o.
• Puerto Rico
  • Ponce, Puerto Rico, 00716
    • Ponce School of Medicine
  • Ponce, Puerto Rico, 00717-1321
    • Edificio Parra
  • San Juan, Puerto Rico, 00918
    • Mindful Medical Research
• Romania
  • Bucharest, Romania, 011172
    • Spitalul Clinic "Sf. Maria"
  • Iasi, Romania, 700661
    • Spitalul Clinic de Recuperare
• Russian Federation
  • Barnaul, Russian Federation, 656024
    • State Healthcare Institution Regional Clinical Hospital
  • Ekaterinburg, Russian Federation, 620102
    • State Healthcare Institution
  • Ekaterinburg, Russian Federation, 620149
    • State Educational Institution of Higher Professional Education Ural State Medical Academy of Federal
  • Ekaterinburg, Russian Federation, 620149
    • State Educational Institution of Higher Professional Education
  • Ekaterinburg, Russian Federation, 620219
    • Ltd.Medical Association "Novaya Bolnitsa"
  • Kemerovo, Russian Federation, 650099
    • State Healthcare Institution Regional Clinical Hospital for War Veterans
  • Moscow, Russian Federation, 115522
    • Rheumatology Research Institute of Russian Academy of Medical Sciences
  • Moscow, Russian Federation, 115093
    • Russian State Medical University Moscow Faculty City Clinical Hospital #4
  • Petrozavodsk, Russian Federation, 185019
    • GUZ Republican Hospital n.a. Baranov
  • Saint-Petersburg, Russian Federation, 197341
    • Federal North-West Medical Research Centre
  • St. Petersburg, Russian Federation, 194291
    • Clinical Hospital #122 named after L.G. Sokolov of the Federal Medical-Biological Agency
  • St. Petersburg, Russian Federation, 198260
    • St. Petersburg State Institution of Healthcare Consultative-diagnostic Center #85
  • St. Petersburg,, Russian Federation, 190068
    • Saint-Petersburg State Budgetary Healthcare Institution "Clinical Rheumathology Hospital #25"
  • Tomsk, Russian Federation, 634063
    • Regional State Budget Institution Of Healthcare
  • Tomsk, Russian Federation, 634063
    • Regional State Budgetary Healthcare Institution of Tomsk Regional Clinical Hospital
  • Novosibirsk Region
    • Novosibirsk City, Novosibirsk Region, Russian Federation, 630047
      • City Clinical Hospital # 1
    • Novosibirsk City, Novosibirsk Region, Russian Federation, 630091
      • "Consultative Diagnostic Rheumatology Center ""Healthy Joints"", LLC"
  • Sestroretsk, Russia
    • Saint-Petersburg, Sestroretsk, Russia, Russian Federation, 197706
      • State Healthcare Institution City Hospital # 40 of Administrative Health Resort District
  • Smolensk Region
    • Smolensk, Smolensk Region, Russian Federation, 214019
      • Smolensk State Medical Academy
• Slovakia
  • Bratislava, Slovakia, 82606
    • Reumatologicka ambulancia, Poliklinika Ruzinov
  • Bratislava, Slovakia, 832 99
    • NOVAPHARM s.r.o -Zeleznicna NaP, Reumatologicka ambulancia
  • Dunajska Streda, Slovakia, 92901
    • AAGS, s.r.o. , nestatne zdravotnicke zariadenie
  • Kosice, Slovakia, 040 01
    • Interna a reumatologicka ambulancia
  • Nove Zamky, Slovakia, 94001
    • Ecclesia, s.r.o Reumatologicka ambulancia
  • Piestany, Slovakia, 92112
    • Narodny ustav reumatickych chorob
  • Poprad, Slovakia, 058 01
    • Reumatologicka ambulancia, MUDr. Zuzana Cizmarikova, s.r.o.
  • Rimavska Sobota, Slovakia, 979 01
    • Reumatologicka ambulancia, REUMEX, s.r.o.
  • Senica, Slovakia, 905 01
    • Reumatologicka ambulancia, Nestatne zdravotnicke zariadenie
  • Zilina, Slovakia, 010 01
    • Nestatna reumatologicka ambulancia, MUDr. Pavol Polak s.r.o.
• Spain
  • Barcelona, Spain, 08003
    • Hospital del Mar
  • Coruna, Spain, 15006
    • Complejo Hospitalario Universitario A Coruña
  • Madrid, Spain, 28041
    • Hospital Universitario 12 de Octubre
  • Madrid, Spain, 28046
    • Hospital Universitario de La Paz
  • Malaga, Spain, 29009
    • Hospital Civil. Hospital Regional Universitario Carlos Haya
  • Sevilla, Spain, 41009
    • Hospital Universitario Virgen Macarena
  • Sevilla, Spain, 41014
    • Hospital Nuestra Senora de Valme
  • Sevilla, Spain, 41700
    • Hospital El Tomillar
  • Valencia, Spain, 46026
    • Hospital Universitari i Politecnic La Fe de Valencia
  • A Coruna
    • Santiago De Compostela, A Coruna, Spain, 15705
      • Hospital Nuestra Señora de La Esperanza
    • Santiago de Compostela, A Coruna, Spain, 15706
      • Hospital Clinico Universitario de Santiago
  • Badajoz
    • Merida, Badajoz, Spain, 06800
      • Hospital de Mérida
  • Cantabria
    • Santander, Cantabria, Spain, 39008
      • Hospital Universitario Marques de Valdecilla
  • Vizcaya
    • Barakaldo, Vizcaya, Spain, 48903
      • Hospital Universitario Cruces
    • Bilbao, Vizcaya, Spain, 48013
      • Hospital de Basurto
• Sweden
  • Falun, Sweden, 791 82
    • Falu Lasarett
  • Jonkoping, Sweden, 551 85
    • Länssjukhuset Ryhov
  • Malmo, Sweden, 205 02
    • Skanes Universitetssjukhus i Malmo Reumamottagningen
  • Sundsvall, Sweden, 851 86
    • Sundsvalls sjukhus
  • Umea, Sweden, 901 85
    • Norrlands Universitetssjukhus
  • Uppsala, Sweden, 75185
    • Akademiska University hospital
• Taiwan
  • Changhua, Taiwan, 500
    • Changhua Christian Hospital
  • Kaohsiung, Taiwan, 807
    • Kaohsiung Medical University Chung-Ho Memorial Hospital
  • Kaohsiung, Taiwan, 813
    • Kaohsiung Veterans General Hospital
  • Taichung, Taiwan, 407
    • Taichung Veterans General Hospital
  • Tainan, Taiwan, 704
    • National Cheng Kung University Hospital
  • Taipei, Taiwan, 100
    • National Taiwan University Hospital
  • Taipei, Taiwan, 112
    • Taipei Veterans General Hospital
  • Kaohsiung County
    • Niao Sung Hsiang, Kaohsiung County, Taiwan, 833
      • Chang Gung Medical Foundation-
  • Taoyuan County
    • Kwei-Shan, Taoyuan County, Taiwan, 333
      • Chang Gung Medical Foundation-Linkou Branch
• Thailand
  • Bangkok, Thailand, 10700
    • Siriraj Hospital, Mahidol University
  • Bangkok, Thailand, 10400
    • Rheumatology Unit, Department of Internal Medicine, Rajavithi Hospital
  • Bangkok
    • Rajathevee, Bangkok, Thailand, 10400
      • Rheumatology Unit, Department of Internal Medicine, Phramongkutklao Hospital
  • Chiang MAI
    • Amphoe Mueang, Chiang MAI, Thailand, 50200
      • Division of Rheumatology, Department of Internal Medicine, Faculty of Medicine,
  • Khonkaen
    • Muang District, Khonkaen, Thailand, 40002
      • Division of Allergy-Immunology-Rheumatology, Department of Medicine, Faculty of Medicine
• Turkey
  • Ankara, Turkey, 06100
    • Hacettepe University Medical Faculty
  • Izmir, Turkey, 35340
    • Dokuz Eylul Universitesi Arastirma Uygulama Hastanesi
  • Izmir
    • Bornova, Izmir, Turkey, 35100
      • Ege University Medical Faculty
• Ukraine
  • Kharkiv, Ukraine, 61178
    • Municipal Establishment of Health Care "Kharkiv City Clinical Hospital #8", Dept. of Rheumatology
  • Kyiv, Ukraine, 04053
    • State Institution Republican Clinical Hospital of the Ministry of Health of Ukraine
  • Kyiv, Ukraine, 04114
    • State Establishment "Institute of Gerontology of NAMS of Ukraine n.a. D.F. Chebotareva"
  • Lviv, Ukraine, 79011
    • Municipal City Clinical Hospital #4, Policlinic Care
  • Odesa, Ukraine, 65026
    • "Multifield Medical Center of Odesa National Medical University ""University Clinic #1"""
  • Odesa, Ukraine, 65026
    • Multifield Medical Center of Odesa National Medical University "University Clinic #1"
  • Simferopol Crimea, Ukraine, 95017
    • CRIMEAN Republican Institution, "Clinical Hospital n.a. M.O. Semashko"
  • Vinnitsa, Ukraine, 21018
    • Vinnitsa Regional Clinical Hospital n.a. Pirogov
  • Zaporizhzhia, Ukraine, 69118
    • Municipal Establishment "City Hospital#7of Zaporizhzhia State Medical University
  • Crimea
    • Simferopol, Crimea, Ukraine, 95017
      • Crimean Republican Institution "Clinical Territorial Medical Association "University Clinic",
• United Kingdom
  • Cannock, United Kingdom, WS11 5XY
    • The Royal Wolverhampton NHS Trust
  • Newcastle Upon Tyne, United Kingdom, NE1 4LP
    • Royal Victoria Infirmary
  • Wirral, United Kingdom, CH49 5PE
    • Wirral University Teaching Hospital NHS Foundation Trust-Arrowe Park Hospital
  • WEST Midlands
    • Dudley, WEST Midlands, United Kingdom, DY1 2HQ
      • Dudley Group of Hospitals NHS Trust
• United States
  • Alabama
    • Birmingham, Alabama, United States, 35294
      • University of Alabama at Birmingham
    • Huntsville, Alabama, United States, 35801
      • Rheumatology Associates of North Alabama, PC
  • Arizona
    • Gilbert, Arizona, United States, 85234
      • Arthrocare, Arthritis Care & Research, PC
    • Phoenix, Arizona, United States, 85032
      • Arizona Arthritis & Rheumatology Associates, P.C.
    • Scottsdale, Arizona, United States, 85251
      • Radiant Research, Inc.
    • Tucson, Arizona, United States, 85704
      • Catalina Pointe Clinical Research
  • Arkansas
    • Hot Springs, Arkansas, United States, 71913
      • CHI St. Vincent Medical Group Hot Springs
    • Jonesboro, Arkansas, United States, 72401
      • NEA Baptist Clinic
    • Little Rock, Arkansas, United States, 72201
      • Osborne Research Center, LLC
    • Little Rock, Arkansas, United States, 72205
      • Little Rock Diagnostic Clinic, PA
  • California
    • Fair Oaks, California, United States, 95628
      • Med Investigations, Inc.
    • Huntington Beach, California, United States, 92646
      • Talbert Medical Group
    • La Jolla, California, United States, 92093
      • University of California San Diego Center for Innovative Therapy
    • Los Angeles, California, United States, 90095
      • University of California Los Angeles
    • Los Angeles, California, United States, 90033
      • Keck Medicine of USC
    • Los Angeles, California, United States, 90033
      • University of Southern California (USC) Norris Comprehensive Cancer Center
    • Los Angeles, California, United States, 90033
      • University of Southern California (USC) Norris Comprehensive Cancer Center-
    • Los Angeles, California, United States, 90095-6984
      • Ronald Reagan UCLA Medical Center, Drug Information Center
    • Palo Alto, California, United States, 94304
      • Stanford University School of Medicine
    • Roseville, California, United States, 95661
      • Office of Anupama Bhat, MD
    • San Diego, California, United States, 92108
      • San Diego Arthritis Medical Clinic
    • Santa Maria, California, United States, 93454
      • Pacific Arthritis Center Medical Group
    • Stanford, California, United States, 94305
      • Stanford Health Services - Medical Specialty Clinics
    • Upland, California, United States, 91786
      • Inland Rheumatology Clinical Trials, Inc.
  • Colorado
    • Boulder, Colorado, United States, 80304
      • Boulder Medical Center, PC
    • Colorado Springs, Colorado, United States, 80910
      • Arthritis Associates and Osteoporosis Center of Colorado Springs
  • Connecticut
    • Farmington, Connecticut, United States, 06030-5353
      • University of Connecticut Health Center
    • Hamden, Connecticut, United States, 06518
      • Arthritis & Osteoporosis Center, PC
    • Trumbull, Connecticut, United States, 06611
      • New England Research Associates, LLC
  • Delaware
    • Newark, Delaware, United States, 19713
      • Delaware Arthritis and Osteoporosis Center
  • Florida
    • Aventura, Florida, United States, 33180
      • Arthritis and Rheumatic Disease Specialties
    • Daytona Beach, Florida, United States, 32114
      • Allergy, Asthma, Arthritis, & Lung
    • DeBary, Florida, United States, 32713
      • Physicians Research Alliance LLC
    • Gainesville, Florida, United States, 32607
      • Southeastern Arthritis Center
    • Gainesville, Florida, United States, 32607
      • Southeastern Imaging and Diagnostics
    • Gainesville, Florida, United States, 32607
      • Southeastern Integrated Medical PL d/b/a Florida Medical Research Institute
    • Gainesville, Florida, United States, 32607
      • Southeastern Integrated Medical, PL, d/b/a Florida Medical Research Institute
    • Jacksonville, Florida, United States, 32216
      • Jacksonville Center for Clinical Research
    • Lake Mary, Florida, United States, 32746
      • Florida Arthritis Center, P.L.
    • Largo, Florida, United States, 33777
      • BayCare Outpatient Imaging at Bardmoor
    • Miami, Florida, United States, 33173
      • Center for Arthritis and Rheumatic Diseases
    • Naples, Florida, United States, 34102
      • Jeffrey Alper MD Research
    • New Port Richey, Florida, United States, 34652
      • Suncoast Clinical Research, Inc.
    • Ocala, Florida, United States, 34474
      • Ocala Rheumatology Research Center
    • Orlando, Florida, United States, 32804
      • Dr. Jeffrey E. Poiley, MD , Office of
    • Ormond Beach, Florida, United States, 32174
      • Millennium Research
    • Pinellas Park, Florida, United States, 33782
      • DMI Research, Inc.
    • Port Richey, Florida, United States, 34668
      • Florida Arthritis & Osteoporosis Center
    • Port Richey, Florida, United States, 34668
      • Gulf Coast Medical Center
    • Saint Petersburg, Florida, United States, 33782
      • Suncoast Medical Clinic
    • South Miami, Florida, United States, 33143
      • Miami Research Associates
    • South Miami, Florida, United States, 33143
      • Arthritis & Rheumatic Care Center
    • Tamarac, Florida, United States, 33321
      • West Broward Rheumatology Associates, Inc.
    • Tampa, Florida, United States, 33614
      • BayCare Medical Group, Inc
    • Venice, Florida, United States, 34292
      • Lovelace Scientific Resources
    • Venice, Florida, United States, 34292
      • Venice Arthritis Center
    • Zephyrhills, Florida, United States, 33542
      • Florida Medical Clinic, P.A.
  • Georgia
    • Atlanta, Georgia, United States, 30342
      • Arthritis and Rheumatology of Georgia P.C.
    • Decatur, Georgia, United States, 30333
      • Jeffrey D. Lieberman, MD, PC
    • Marietta, Georgia, United States, 30060
      • Marietta Rheumatology Associates
  • Idaho
    • Boise, Idaho, United States, 83702
      • St. Luke's Clinic - Rheumatology
    • Boise, Idaho, United States, 83702
      • St. Luke's Intermountain Research Center
    • Boise, Idaho, United States, 83702
      • St. Luke's Clinic
    • Idaho Falls, Idaho, United States, 83404
      • Institute of Arthritis Research
    • Meridian, Idaho, United States, 83642
      • St. Luke's Clinic - Rhematology
  • Illinois
    • Maywood, Illinois, United States, 60153
      • Loyola University Medical Center
    • Morton Grove, Illinois, United States, 60053
      • Illinois Bone and Joint Institute, LLC
    • Rockford, Illinois, United States, 61114
      • Rockford Orthopedic Associates
    • Rockford, Illinois, United States, 61103-3692
      • Rockford Health Physicians
    • Springfield, Illinois, United States, 62702
      • Springfield Clinic
    • Springfield, Illinois, United States, 62703
      • Springfield Clinic - Clinical Research
    • Vernon Hills, Illinois, United States, 60061
      • Deerbrook Medical Associates
  • Indiana
    • Indianapolis, Indiana, United States, 46227
      • Diagnostic Rheumatology and Research PC
  • Iowa
    • Cedar Rapids, Iowa, United States, 52403
      • Physician's Clinic of Iowa, P.C.
    • Dubuque, Iowa, United States, 52002
      • Medical Associates Clinic, PC
  • Kansas
    • Overland Park, Kansas, United States, 66209
      • Kansas City Internal Medicine
    • Wichita, Kansas, United States, 67203
      • Professional Research Network of Kansas, LLC
    • Wichita, Kansas, United States, 67208
      • Via Christi Clinic, P.A.
  • Kentucky
    • Lexington, Kentucky, United States, 40504
      • Bluegrass Community Research, Inc.
  • Louisiana
    • Baton Rouge, Louisiana, United States, 70809
      • Ochsner Clinic Foundation - Baton Rouge
    • New Orleans, Louisiana, United States, 70115
      • Louisiana State University Health Sciences Center
  • Maine
    • Portland, Maine, United States, 04102
      • Rheumatology Associates
  • Maryland
    • Cumberland, Maryland, United States, 21502
      • Klein and Associates, MD, PA
    • Frederick, Maryland, United States, 21702
      • The Arthritis Treatment Center
    • Wheaton, Maryland, United States, 20902
      • The Center for Rheumatology and Bone Research
  • Massachusetts
    • Hyannis, Massachusetts, United States, 02601
      • Clinical Research Center of Cape Cod, Inc.
    • Worcester, Massachusetts, United States, 01605
      • Reliant Medical Group, Inc.
    • Worcester, Massachusetts, United States, 01608
      • Reliant Medical Group, Inc. at Worcester Medical Center
  • Michigan
    • Battle Creek, Michigan, United States, 49015
      • Bronson Internal Medicine and Rheumatology
    • Bingham Farms, Michigan, United States, 48025
      • Quest Research Institiute
    • Kalamazoo, Michigan, United States, 49048
      • Borgess Research Institute
    • Southfield, Michigan, United States, 48034
      • Farmbrook Radiology Associates
  • Minnesota
    • Edina, Minnesota, United States, 55435
      • Arthritis and Rheumatology Consultants, P.A.
  • Mississippi
    • Tupelo, Mississippi, United States, 38801
      • North Mississippi Medical Clinics, Inc.
  • Missouri
    • Columbia, Missouri, United States, 65212
      • University of Missouri-Columbia
    • Columbia, Missouri, United States, 65203
      • University Physicians - Woodrail Clinic
  • Nebraska
    • Lincoln, Nebraska, United States, 68516
      • Physician Research Collaboration, LLC
    • Massachusetts, Nebraska, United States, 01605
      • Clinical Pharmacology Study Group
    • Omaha, Nebraska, United States, 68114
      • Westroads Clinical Research, Inc.
    • Omaha, Nebraska, United States, 68134
      • Heartland Clinic Research, Inc.
  • New Hampshire
    • Lebanon, New Hampshire, United States, 03756
      • Dartmouth-Hitchcock Medical Center
  • New Jersey
    • Teaneck, New Jersey, United States, 07666
      • Rheumatology Associates of North Jersey
    • Voorhees, New Jersey, United States, 08043
      • Arthritis, Rheumatic & Back Disease Associates
  • New York
    • Albany, New York, United States, 12203
      • The Center For Rheumatology, Llp
    • Binghamton, New York, United States, 13905
      • Regional Rheumatology Associates
    • Olean, New York, United States, 14760
      • Southern Tier Arthritis and Rheumatism
    • Orchard Park, New York, United States, 14127
      • Buffalo Rheumatology and Medicine, PLLC
    • Rochester, New York, United States, 14618
      • AAIR Research Center
  • North Carolina
    • Asheville, North Carolina, United States, 28801
      • Asheville Rheumatology & Osteoporosis Research Associates, P.A.
    • Asheville, North Carolina, United States, 28803
      • Asheville Rheumatology & Osteoporosis Research Associates, PA
    • Charlotte, North Carolina, United States, 28210
      • DJL Clinical Research, PLLC
    • Hickory, North Carolina, United States, 28602
      • PMG Research Hickory, LLC
    • Hickory, North Carolina, United States, USA 28602
      • PMG Research of Hickory
    • Rocky Mount, North Carolina, United States, 27804
      • Boice-Willis Clinic
  • North Dakota
    • Minot, North Dakota, United States, 58701
      • Trinity Health Center - Medical Arts
  • Ohio
    • Cincinnati, Ohio, United States, 45219
      • Cincinnati Rheumatic Disease Study Group, Inc.
    • Dayton, Ohio, United States, 45417
      • STAT Research, Inc.
    • Mayfield, Ohio, United States, 44143
      • Office of David R. Mandel, MD, Inc.
  • Oklahoma
    • Oklahoma City, Oklahoma, United States, 73112
      • Lynn Health Science Institute
    • Oklahoma City, Oklahoma, United States, 73104
      • Oklahoma Medical Research Foundation (OMRF)
  • Pennsylvania
    • Bethlehem, Pennsylvania, United States, 18015
      • East Penn Rheumatology Associates, Pc
    • Duncansville, Pennsylvania, United States, 16635
      • Altoona Center for Clinical Research
    • Willow Grove, Pennsylvania, United States, 19090
      • Rheumatic Disease Associates, Ltd.
    • Wyomissing, Pennsylvania, United States, 19610
      • Clinical Research Center of Reading LLP
  • South Carolina
    • Greenville, South Carolina, United States, 29601
      • Piedmont Arthritis Clinic, PA
  • Tennessee
    • Hixson, Tennessee, United States, 37343
      • Arthritis Associates, PLLC
    • Jackson, Tennessee, United States, 38305
      • Arthritis Clinic
    • Jackson, Tennessee, United States, 38305
      • West Tennessee Research Institute
    • Knoxville, Tennessee, United States, 37909-1907
      • Rheumatology Consultants, PLLC
    • Nashville, Tennessee, United States, 37203
      • Vanderbilt University Medical Center
  • Texas
    • Allen, Texas, United States, 75013
      • Office of John P. Lavery, MD, PA
    • Austin, Texas, United States, 78705
      • Austin Rheumatology Research, PA
    • Dallas, Texas, United States, 75231
      • Metroplex Clinical Research Center
    • Dallas, Texas, United States, 75231
      • Baylor Research Institute
    • Dallas, Texas, United States, 75231
      • Arthritis Care And Diagnostic Center, P.A.
    • Fort Worth, Texas, United States, 76107
      • University of North Texas Health Science Center at Fort Worth
    • Houston, Texas, United States, 77034
      • Accurate Clinical Research, Inc.
    • Houston, Texas, United States, 77074
      • Houston Institute for Clinical Research
    • Lubbock, Texas, United States, 79424
      • Arthritis and Osteoporosis Associates, LLP
    • Mesquite, Texas, United States, 75150
      • SouthWest Rheumatology Research, LLC
  • Washington
    • Seattle, Washington, United States, 98101
      • Virginia Mason Medical Center
    • Seattle, Washington, United States, 98122
      • Seattle Rheumatology Associates
    • Seattle, Washington, United States, 98133
      • The Seattle Arthritis Clinic
    • Tacoma, Washington, United States, 98405
      • Tacoma Center of Arthritis Research, PS
    • Vancouver, Washington, United States, 98664
      • The Vancouver Clinic, Inc. PS
  • West Virginia
    • Clarksburg, West Virginia, United States, 26301
      • Mountain State Clinical Research
  • Wisconsin
    • Onalaska, Wisconsin, United States, 54650
      • Gundersen Clinic, Ltd

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• Subjects who have participated in a randomized "qualifying" study of CP-690,550 for the treatment of rheumatoid arthritis

Vaccine sub-study visit

• Subjects actively participating in Study A3921024 must have completed at least 3 months of continuous 10 mg BID CP-690,550 treatment in A3921024 as defined by >80% compliance with prescribed dose consumption of CP-690,550 over the previous 3 months.

Exclusion Criteria:

• Serious medical conditions that would make treatment with CP-690,550 potentially unsafe

Vaccine sub-study visit

1. Any documented influenza or pneumococcal infection within the last 3 months prior to randomization in this study
2. Received any vaccine within 1 month prior to randomization in this study
3. Received an influenza vaccine within 6 months or a pneumococcal vaccine within 5 years of randomization in this study.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Non-Randomized
• Interventional Model: Parallel Assignment
• Masking: None (Open Label)

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Open-Label Active Treatment Enrolled from Phase 2; Patients enrolling from Phase 2 studies	Drug: CP-690,550; 5 mg PO BID open label; may increase to 10 mg PO BID to provide greater control of RA if no related AEs are present. May be off study drug temporarily for up to 28 days for mild to moderate AEs.; Drug: CP-690,550; 10 mg PO BID open label; may decrease to 5 mg PO BID for mild to moderate AEs. May be off study drug temporarily for up to 28 days for mild to moderate AEs.
Experimental: Open-Label Active Treatment Enrolled from Phase 3; Patients enrolling from Phase 3 studies	Drug: CP-690,550; 5 mg PO BID open label; may increase to 10 mg PO BID to provide greater control of RA if no related AEs are present. May be off study drug temporarily for up to 28 days for mild to moderate AEs.; Drug: CP-690,550; 10 mg PO BID open label; may decrease to 5 mg PO BID for mild to moderate AEs. May be off study drug temporarily for up to 28 days for mild to moderate AEs.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Initial Period: Primary Endpoints Were Standard Laboratory Safety Data (Chemistry, Hematology, Etc.) and Adverse Event (AE) Reports	Treatment-emergent non serious AEs by System Organ Class (SOC) (all causalities) and Laboratory Test Abnormalities (without regard to baseline) The stated number of participants analyzed was the total number of participants in each group (AEs). The actual number of participants analyzed for each laboratory parameter varied, and is provided for each. Abs=absolute; ALT=alanine aminotransferase; AST=aspartate aminotransferase; ESR=erythrocyte sedimentation rate; GGT=gamma glutamyl transferase; hgb=hemoglobin; HDL=high density lipids; LDL=low density lipids; LLN=lower limit of normal; qual=qualitative; Tot=total; ULN=upper limit of normal; WBC=white blood cell	Includes laboratory test abnormality data for all visits and adverse event data up to 999 days after last dose of study drug
Extension Period: Number of Participants With Treatment Emergent Adverse Events (AEs), Serious Adverse Events (SAEs)	An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. A treatment emergent AE was defined as an event that emerged during the treatment period that was absent before treatment, or worsened during the treatment period relative to the pretreatment state. AEs included both serious and non-serious adverse events.	Baseline (Day 1 at Entry of Extension Period) up to 28 days after last study drug dose in Extension Period (13 Months)
Extension Period: Number of Participants With Laboratory Test Abnormalities	Criteria for laboratory abnormalities: hemoglobin (Hg), hematocrit, red blood cell (RBC), high density lipoprotein (HDL) cholesterol:<0.8*lower limit of normal (LLN), platelet<0.5*LLN/>1.75*upper limit of normal (ULN), white blood cell (WBC)<0.6*LLN/>1.5*ULN, lymphocyte, neutrophil, protein, albumin <0.8*LLN/>1.2*ULN, basophil, eosinophil, monocyte, low density lipoprotein (LDL) cholesterol: >1.2*ULN; bilirubin>1.5*ULN, aspartate amino transferase(AT), alanine AT, gammaglutamyl transferase, alkaline phosphatase:>3.0*ULN; blood urea nitrogen, creatinine, cholesterol, triglyceride:>1.3*ULN; sodium <0.95*LLN/>1.05*ULN, potassium, chloride, calcium, bicarbonate: <0.9*LLN/>1.1*ULN; glucose<0.6*LLN/>1.5*ULN; Urine (specific gravity<1.003/>1.030, pH<4.5/>8, glucose, ketone, protein, blood/Hg(>=1; RBC, WBC>=20; creatinine kinase>2*ULN).	Baseline (Day 1 at Entry of Extension Period) up to 28 days after last study drug dose in Extension Period (13 Months)
Initial Period: The Long Term Safety and Tolerability of CP-690,550 5 Milligrams (mg) Twice Daily (BID) and 10 mg BID for the Treatment of Rheumatoid Arthritis	Treatment-emergent AEs by SOC (all causalities) - all participants, by time. Data presented for Post Month 96 includes data up to and including Month 114.	Includes AEs for every visit and up to 999 days after last dose of study drug
Extension Period: Percentage of Participants With Adverse Events and Who Discontinued Treatment Due to Adverse Events to Assess Long-term Safety and Tolerability of Tofacitinib	Long term safety and tolerability of Tofacitinib was measured as following: percentage (%) of participants with AEs, percentage of participants who discontinued due to AEs. An AE is any untoward medical occurrence in participant who received study drug without regard to possibility of causal relationship.	Baseline (Day 1 at Entry of Extension Period) up to Month 6 of Extension Period; Month 6 of Extension Period to Month 12 of Extension Period

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Initial Period: Percentage of Patients With American College of Rheumatology (ACR) 20, 50, and 70 Responses	The stated number of participants analyzed was the total number of participants in each group. The actual number of participants analyzed on each occasion varied, and is provided for each visit presented. ACR20 is defined as a 20% improvement from baseline in tender/painful joint count and swollen joint count, and at least 3 of the following 5 variables: Subject's Global Assessment of Arthritis, Physician's Global Assessment of Arthritis, Subject's Assessment of Arthritis Pain, Health Assessment Questionnaire - Disability Index, C-Reactive Protein (CRP). ACR50 is a 50% improvement and ACR70 a 70% improvement in these variables.	Every visit until study completion
Extension Period: Percentage of Participants With American College of Rheumatology (ACR) 20, 50, and 70 Responses	ACR20=20 percent (%) improvement from baseline (Month 0 at entry of Initial Period) in tender/painful joint count and swollen joint count, and in at least 3 of 5 variables: participant's global assessment of arthritis (PtGA), physician's global assessment of arthritis (PGA), participant's assessment of arthritis pain (PtA), HAQ-DI, C-reactive protein. ACR50 is a 50% improvement and ACR70 is a 70% improvement in these variables. PtGA: participant assessed overall disease activity, score: 0 (no arthritis) to 10 (extreme arthritis), higher score=more arthritis. PGA: physician judged participant's overall disease activity, score: 0 (no arthritis) to 10 (extreme arthritis), higher score=more arthritis. PtA: participant assessed arthritis pain by 100 millimeter (mm) visual analogue scale, score: 0 mm (no pain) to 100 mm (extreme pain), higher score=more pain. HAQ-DI: functional disability evaluation, score: 0 (no difficulty) to 3 (extreme difficulty), higher score=more disability.	Month 3, 6, 9 and 12 of Extension Period
Initial Period: Area Under American College of Rheumatology (ACR) n Curve	No data were collected for this endpoint because it was removed from the protocol in a previous amendment.	Not applicable as no data were collected for this endpoint.
Initial Period: Disease Activity Score (DAS)28 (C-reactive Protein [CRP]) and DAS28 (Erythrocyte Sedimentation Rate [ESR])	Descriptive statistics for DAS28-3 (CRP) and DAS28-4 (ESR). The stated number of participants analyzed was the total number of participants in each group. The actual number of participants analyzed on each occasion varied, and is provided for each visit presented. DAS28 is a composite score, calculated using a mathematical formula, and is derived from the number of tender/painful joints (out of 28), number of swollen joints (out of 28), and a blood marker of inflammation (ESR or CRP). DAS28-4 also includes a score of general health in the formula. The score range is from 0 to 9.4, with a higher score indicating more disease activity. A score of >5.1 indicates active disease, a score of ≤3.2 indicates low disease activity, and a score of <2.6 indicates disease remission.	Every visit until study completion
Extension Period: Change From Baseline in Disease Activity Score (DAS) 28-3 C-Reactive Protein (CRP)(DAS28-3 CRP) and DAS28-4 Erythrocyte Sedimentation Rate (ESR)(DAS28-4 ESR) at Month 3, 6, 9 and 12	DAS28 is composite score, calculated using mathematical formula, derived from: 1) tender/painful joints count, out of 28 joints (TJC28), 2) swollen joints count, out of 28 joints (SJC28), 3) blood marker of inflammation (ESR [millimeter per hour] or CRP [milligram per liter]). DAS28-4 also include score of general health (GH). GH is general health or participants' global assessment of disease activity on 100 mm visual analog scale (GH score: 0 mm [very well] to 100 mm [extremely bad], higher scores = worse health condition). DAS28-3(CRP) = (0.56*sqrt[TJC28] + 0.28*sqrt[SJC28] + 0.36*ln[CRP+1]) *1.10 + 1.15) and DAS28-4(ESR) = (0.56*sqrt[TJC28] + 0.28*sqrt[SJC28] + 0.70*ln[ESR] + 0.014*GH), where sqrt = square root, ln = natural logarithm. DAS28-4 ESR and DAS28-3 CRP: score ranges from 0 (none) to 9.4 (extreme disease activity), with a higher score indicating more disease activity. Score of <=3.2 indicate low disease activity and score of <2.6 indicate disease remission.	Baseline (Month 0 at the entry of Initial period); Month 3, 6, 9 and 12 of Extension Period
Initial Period: Number (%) of Participants With DAS28-4 (ESR) and DAS28-3 (CRP) <2.6 and ≤3.2	Percent participants with DAS28-4 (ESR) <2.6 and ≤3.2 and percent participants with DAS28-3 (CRP) <2.6 and ≤3.2. The stated number of participants analyzed was the total number of participants in each group. The actual number of participants analyzed on each occasion varied, and is provided for each visit presented. DAS28 is a composite score, calculated using a mathematical formula, and is derived from the number of tender/painful joints (out of 28), number of swollen joints (out of 28), and a blood marker of inflammation (ESR or CRP). DAS28-4 also includes a score of general health in the formula. The score range is from 0 to 9.4, with a higher score indicating more disease activity. A score of >5.1 indicates active disease, a score of ≤3.2 indicates low disease activity, and a score of <2.6 indicates disease remission.	Every visit until study completion
Extension Period: Percentage of Participants With DAS28-4 (ESR) and DAS28-3 (CRP) Less Than (<) 2.6 and Less Than or (<=) 3.2	DAS28 is composite score, calculated using mathematical formula, derived from: 1) tender/painful joints count, out of 28 joints (TJC28), 2) swollen joints count, out of 28 joints (SJC28), 3) blood marker of inflammation (ESR [millimeter per hour] or CRP [milligram per liter]). DAS28-4 also include score of GH. GH is general health or participants' global assessment of disease activity on 100 mm visual analog scale (GH score: 0 mm [very well] to 100 mm [extremely bad], higher scores = worse health condition). DAS28-3(CRP) = (0.56*sqrt[TJC28] + 0.28*sqrt[SJC28] + 0.36*ln[CRP+1]) *1.10 + 1.15) and DAS28-4(ESR) = (0.56*sqrt[TJC28] + 0.28*sqrt[SJC28] + 0.70*ln[ESR] + 0.014*GH), where sqrt = square root, ln = natural logarithm. DAS28-4 ESR and DAS28-3 CRP: score range is from 0 (none) to 9.4 (extreme disease activity), with a higher score indicating more disease activity. Score of <=3.2 indicate low disease activity and score of <2.6 indicate disease remission.	Baseline (Day 1 at the entry of Extension period); Month 3, 6, 9 and 12 of Extension Period
Initial Period: Health Assessment Questionnaire - Disability Index (HAQ-DI) Score	Change from baseline by visit. HAQ-DI scores range from 0 to 3, where lower score implies less disease. A reduction from baseline in score indicates an improvement in condition. A clinically meaningful decrease from baseline is defined as a decrease of at least 0.22 units. The stated number of participants analyzed was the total number of participants in each group. The actual number of participants analyzed on each occasion varied, and is provided for each visit presented.	Every visit until study completion
Extension Period: Change From Baseline in Health Assessment Questionnaire - Disability Index (HAQ-DI) Score at Month 3, 6, 9 and 12	HAQ-DI assesses the degree of difficulty a participant has experienced during the past week in 8 categories of daily living activities: dressing/grooming; arising; eating; walking; reach; grip; hygiene; and other activities. Each activity category consisted of 2-3 questionnaire. Each questionnaire was scored on a 4-point scale from 0 to 3: 0=no difficulty; 1=some difficulty; 2=much difficulty; 3=unable to do. Any activity that required assistance from another individual or required the use of an assistive device was adjusted to a score of 2 to represent a more limited functional status. Overall score was computed as the sum of total scores divided by the number of questionnaire answered. Total possible HAQ-DI score range: 0 (least difficulty) and 3 (extreme difficulty), where higher scores indicate more difficulty while performing daily living activities.	Baseline (Month 0 at the entry of Initial Period); Month 3, 6, 9, and 12 of Extension Period
Initial Period: Short-Form-36 Health Survey (SF-36) Score	Change from Baseline for Physical Component and Mental Component Scores by visit. SF-36 is a health status measure of 8 general health domains, each scored on a 0 to 100 scale: physical functioning, role physical, bodily pain, general health, vitality, social functioning, role emotional, and mental health. These domains can be summarized as physical and mental component scores. The domain scores were "normed" and the resulting component scores treated as Z-scores with a scale of negative to positive infinity. A higher score implies less disease. The greater the change from baseline, the greater the improvement. The stated number of participants analyzed was the total number of participants in each group. The actual number of participants analyzed on each occasion varied, and is provided for each visit presented.	Every visit until study completion
Initial Period: FACIT Fatigue Scale, EuroQol EQ 5D, Work Limitations Questionnaire, and RA Healthcare Resource Utilization Questionnaire (RA-HCRU)	Change from Baseline Scores for each: FACIT Fatigue Scale (score range 0 to 52, higher score indicates higher quality of life and an increase from baseline score indicates improvement), EuroQol EQ 5D (index values derived from a measure of central tendency and a measure of dispersion, an increase from baseline indicates improvement, score range 0 to 1), Work Limitations (WL) Physical Demands (covers ability to perform job tasks that involve bodily strength, a decrease from baseline indicates improvement, score range 0 to 100, higher scores indicating greater limitation), and RA Healthcare Resource Utilization Work Performance in Past 3 Months on Days Bothered by RA (assesses healthcare use over previous 3 months, a decrease from baseline indicates improvement, score range 0 to 10). The stated number of participants analyzed was the total number of participants in each group. The actual number of participants analyzed on each occasion varied, and is provided for each visit presented.	Every visit until study completion
Initial Period: Preservation of Joint Structure in Participants Who Had Baseline Radiographs Obtained in Their Qualifying Index Study	Modified Total Sharp Score per visit. Baseline score was the last available assessment from the index study. The Modified Total Sharp Score measures disease progression; increased scores indicate disease progression. Score range 0 (normal) to 448 (worst possible total score). The stated number of participants analyzed was the total number of participants in each group. The actual number of participants analyzed on each occasion varied, and is provided for each visit presented. TSS=Total Sharp Score	Every 6 months until study completion
Vaccine Sub-study. Percent Achieving a Satisfactory Humoral Response to the Pneumococcal Vaccine as Defined by ≥ 2-fold Increase in Antibody Concentrations	Number (%) of participants achieving a satisfactory humoral response to the pneumococcal vaccine as defined by ≥2-fold increase in antibody concentration from vaccine sub-study visit 2 (vaccination baseline) in ≥6 of 12 anti-pneumococcal antigens (serotypes 1, 3, 4, 5, 6B, 7F, 9V, 14, 18C, 19A, 19F, 23F) The number of participants was the number with a determinate antibody titer to the given vaccine antigen within the population. 95% CI is based on Clopper-Pearson exact method for response rate.	From vaccine sub-study visit 2 (baseline) to sub-study visit 4
Vaccine Sub-study. Percent Achieving a Satisfactory Humoral Response to the Seasonal Influenza Vaccine as Defined by ≥ 4-fold Increase in Antibody Titers	Number of participants achieving a satisfactory humoral response to the seasonal influenza vaccine as defined by ≥4-fold increase in antibody titers from visit 2 (vaccination baseline) in ≥2 of 3 influenza antigens (HAI B, HAI H1N1, and HAI H3N2) The number of participants was the number with a determinate antibody titer to the given vaccine antigen within the population. 95% CI is based on Clopper-Pearson exact method for response rate.	From vaccine sub-study visit 2 (baseline) to sub-study visit 4
Vaccine Sub-study. Percentage of Participants Achieving Protective Antibody Titers to the Seasonal Influenza Vaccine as Measured by a Hemagglutination Inhibition (HI) Assay Titer of ≥ 1:40 in ≥ 2 of 3 Influenza Antigens at Vaccine Sub-study Visit 3 and 4	Number (%) of participants achieving protective antibody titers to the seasonal influenza vaccine as measured by an HAI assay titer of ≥1:40 in ≥2 of 3 influenza antigens measured at vaccine sub-study visits 3 and 4. The number of participants was the number with a determinate antibody titer to the given vaccine antigen within the population. 95% CI is based on Clopper-Pearson exact method for response rate.	From vaccine sub-study visit 2 (baseline) to sub-study visit 4
Vaccine Sub-study. Percentage of Participants Who Respond to Each of the 12 Pneumococcal Antigens as Defined by ≥ 2-fold Increase in Antibody Concentrations From Vaccine Sub-study Visit 2 (Vaccination Baseline) Measured at Vaccine Sub-study Visit 4	Number (%) of participants achieving a satisfactory humoral response to the pneumococcal vaccine as defined by ≥2-fold increase in antibody concentration from vaccine sub-study visit 2 (vaccination baseline) in ≥6 of 12 anti-pneumococcal antigens (serotypes 1, 3, 4, 5, 6B, 7F, 9V, 14, 18C, 19A, 19F, 23F) The number of participants was the number with a determinate antibody titer to the given vaccine antigen within the population. 95% CI is based on Clopper-Pearson exact method for response rate.	From vaccine sub-study visit 2 (baseline) to sub-study visit 4
Vaccine Sub-study. Percentage of Participants Who Respond to Each of the 3 Influenza Antigens as Defined by ≥ 4-fold Increase in Antibody Titers From Vaccine Sub-study Visit 2 (Vaccination Baseline) Measured at Vaccine Sub-study Visit 4	Number (%) of participants achieving a satisfactory humoral response to the seasonal influenza vaccine defined as ≥4-fold increase in antibody titers from visit 2 (vaccination baseline) in ≥2 of 3 influenza antigens (HAI B, HAI H1N1, and HAI H3N2). The number of participants was the number with a determinate antibody titer to the given vaccine antigen within the population. 95% CI is based on Clopper-Pearson exact method for response rate.	From vaccine sub-study visit 2 (baseline) to sub-study visit 4
Vaccine Sub-study. Fold Increase of Anti-pneumococcal Antibody Levels to Each of the 12 Pneumococcal Antigens Above Vaccination Baseline Values (Vaccine Sub-study Visit 2) at Vaccine Sub-study Visit 4	Geometric Mean Fold Increase From Baseline of Pneumococcal Antigens Measured at Visit 4. n was the number of participants with valid and determinate assay results for the specified serotype at the given visit. The stated number of participants analyzed was the total number of participants. The actual number of participants analyzed for some serotypes varied, and is provided where it differed from the total number of participants. Confidence Intervals (CIs) were back transformations of a CI based on the Student t distribution for the mean logarithm of the concentrations.	From vaccine sub-study visit 2 (baseline) to sub-study visit 4
Vaccine Sub-study. Fold Increase of Anti-influenza Antibody Levels to Each of the 3 Influenza Antigens Above Vaccination Baseline Values (Vaccine Sub-study Visit 2) at Vaccine Sub-study Visit 4	Geometric Mean Fold Increase From Baseline of Influenza Antigens Measured at Visit 4. n was the number of participants with valid and determinate assay results for the specified HAI strain at the given visit. Confidence Intervals (CIs) were back transformations of a CI based on the Student t distribution for the mean logarithm of the titers.	From vaccine sub-study visit 2 (baseline) to sub-study visit 4
Vaccine Sub-study. Concentrations of Anti-pneumococcal Antibodies at Vaccine Sub-study Visit 3 and 4	Mean pneumococcal concentrations (ug/mL) at vaccine baseline (visit 2) and post-vaccination visits (visits 3 and 4) by serotype. The stated number of participants analyzed was the total number of participants in each group. The actual number of participants analyzed for each serotype varied, and is provided for each individually. ug/mL=micrograms per milliliter	From vaccine sub-study visit 2 (baseline) to sub-study visit 4
Vaccine Sub-study. Titers of Anti-influenza Antibodies at Vaccine Sub-study Visit 3 and 4	Mean influenza antibody titers at visits 3 and 4.	From vaccine sub-study visit 2 (baseline) to sub-study visit 4

Collaborators and Investigators

• Sponsor: Pfizer

Publications and helpful links

General Publications

• Panaccione R, Isaacs JD, Chen LA, Wang W, Marren A, Kwok K, Wang L, Chan G, Su C. Characterization of Creatine Kinase Levels in Tofacitinib-Treated Patients with Ulcerative Colitis: Results from Clinical Trials. Dig Dis Sci. 2021 Aug;66(8):2732-2743. doi: 10.1007/s10620-020-06560-4. Epub 2020 Aug 20. Erratum In: Dig Dis Sci. 2020 Oct 10;:
• Winthrop KL, Curtis JR, Yamaoka K, Lee EB, Hirose T, Rivas JL, Kwok K, Burmester GR. Clinical Management of Herpes Zoster in Patients With Rheumatoid Arthritis or Psoriatic Arthritis Receiving Tofacitinib Treatment. Rheumatol Ther. 2022 Feb;9(1):243-263. doi: 10.1007/s40744-021-00390-0. Epub 2021 Dec 6.
• van der Heijde D, Landewe RBM, Wollenhaupt J, Strengholt S, Terry K, Kwok K, Wang L, Cohen S. Assessment of radiographic progression in patients with rheumatoid arthritis treated with tofacitinib in long-term studies. Rheumatology (Oxford). 2021 Apr 6;60(4):1708-1716. doi: 10.1093/rheumatology/keaa476.
• Cohen SB, Tanaka Y, Mariette X, Curtis JR, Lee EB, Nash P, Winthrop KL, Charles-Schoeman C, Thirunavukkarasu K, DeMasi R, Geier J, Kwok K, Wang L, Riese R, Wollenhaupt J. Long-term safety of tofacitinib for the treatment of rheumatoid arthritis up to 8.5 years: integrated analysis of data from the global clinical trials. Ann Rheum Dis. 2017 Jul;76(7):1253-1262. doi: 10.1136/annrheumdis-2016-210457. Epub 2017 Jan 31.
• Hall S, Nash P, Rischmueller M, Bossingham D, Bird P, Cook N, Witcombe D, Soma K, Kwok K, Thirunavukkarasu K. Tofacitinib, an Oral Janus Kinase Inhibitor: Pooled Efficacy and Safety Analyses in an Australian Rheumatoid Arthritis Population. Rheumatol Ther. 2018 Dec;5(2):383-401. doi: 10.1007/s40744-018-0118-2. Epub 2018 Jun 11.
• Genovese MC, van Vollenhoven RF, Wilkinson B, Wang L, Zwillich SH, Gruben D, Biswas P, Riese R, Takiya L, Jones TV. Switching from adalimumab to tofacitinib in the treatment of patients with rheumatoid arthritis. Arthritis Res Ther. 2016 Jun 23;18:145. doi: 10.1186/s13075-016-1049-3.
• Cohen SB, Tanaka Y, Mariette X, Curtis JR, Lee EB, Nash P, Winthrop KL, Charles-Schoeman C, Wang L, Chen C, Kwok K, Biswas P, Shapiro A, Madsen A, Wollenhaupt J. Long-term safety of tofacitinib up to 9.5 years: a comprehensive integrated analysis of the rheumatoid arthritis clinical development programme. RMD Open. 2020 Oct;6(3):e001395. doi: 10.1136/rmdopen-2020-001395.
• Boyle DL, Soma K, Hodge J, Kavanaugh A, Mandel D, Mease P, Shurmur R, Singhal AK, Wei N, Rosengren S, Kaplan I, Krishnaswami S, Luo Z, Bradley J, Firestein GS. The JAK inhibitor tofacitinib suppresses synovial JAK1-STAT signalling in rheumatoid arthritis. Ann Rheum Dis. 2015 Jun;74(6):1311-6. doi: 10.1136/annrheumdis-2014-206028. Epub 2014 Nov 14.
• Mueller RB, Schulze-Koops H, Furst DE, Cohen SB, Kwok K, Wang L, Killeen T, von Kempis J. Effect of dose adjustments on the efficacy and safety of tofacitinib in patients with rheumatoid arthritis: a post hoc analysis of an open-label, long-term extension study (ORAL Sequel). Clin Rheumatol. 2022 Apr;41(4):1045-1055. doi: 10.1007/s10067-021-05908-z. Epub 2022 Jan 1.
• Kaine J, Tesser J, Takiya L, DeMasi R, Wang L, Snyder M, Soma K, Fan H, Bandi V, Wollenhaupt J. Re-establishment of efficacy of tofacitinib, an oral JAK inhibitor, after temporary discontinuation in patients with rheumatoid arthritis. Clin Rheumatol. 2020 Jul;39(7):2127-2137. doi: 10.1007/s10067-020-04956-1. Epub 2020 Feb 12.
• Wollenhaupt J, Lee EB, Curtis JR, Silverfield J, Terry K, Soma K, Mojcik C, DeMasi R, Strengholt S, Kwok K, Lazariciu I, Wang L, Cohen S. Safety and efficacy of tofacitinib for up to 9.5 years in the treatment of rheumatoid arthritis: final results of a global, open-label, long-term extension study. Arthritis Res Ther. 2019 Apr 5;21(1):89. doi: 10.1186/s13075-019-1866-2.
• Li ZG, Liu Y, Xu HJ, Chen ZW, Bao CD, Gu JR, Zhao DB, An Y, Hwang LJ, Wang L, Kremer J, Wu QZ. Efficacy and Safety of Tofacitinib in Chinese Patients with Rheumatoid Arthritis. Chin Med J (Engl). 2018 Nov 20;131(22):2683-2692. doi: 10.4103/0366-6999.245157.
• Fleischmann R, Wollenhaupt J, Takiya L, Maniccia A, Kwok K, Wang L, van Vollenhoven RF. Safety and maintenance of response for tofacitinib monotherapy and combination therapy in rheumatoid arthritis: an analysis of pooled data from open-label long-term extension studies. RMD Open. 2017 Dec 18;3(2):e000491. doi: 10.1136/rmdopen-2017-000491. eCollection 2017.
• Fleischmann R, Wollenhaupt J, Cohen S, Wang L, Fan H, Bandi V, Andrews J, Takiya L, Bananis E, Weinblatt ME. Effect of Discontinuation or Initiation of Methotrexate or Glucocorticoids on Tofacitinib Efficacy in Patients with Rheumatoid Arthritis: A Post Hoc Analysis. Rheumatol Ther. 2018 Jun;5(1):203-214. doi: 10.1007/s40744-018-0093-7. Epub 2018 Feb 7.
• Mariette X, Chen C, Biswas P, Kwok K, Boy MG. Lymphoma in the Tofacitinib Rheumatoid Arthritis Clinical Development Program. Arthritis Care Res (Hoboken). 2018 May;70(5):685-694. doi: 10.1002/acr.23421. Epub 2018 Apr 2.
• Winthrop KL, Silverfield J, Racewicz A, Neal J, Lee EB, Hrycaj P, Gomez-Reino J, Soma K, Mebus C, Wilkinson B, Hodge J, Fan H, Wang T, Bingham CO 3rd. The effect of tofacitinib on pneumococcal and influenza vaccine responses in rheumatoid arthritis. Ann Rheum Dis. 2016 Apr;75(4):687-95. doi: 10.1136/annrheumdis-2014-207191. Epub 2015 Mar 20.

Helpful Links

• To obtain contact information for a study center near you, click here.

Study record dates

Study Major Dates

• Study Start (Actual): February 5, 2007
• Primary Completion (Actual): November 30, 2016
• Study Completion (Actual): October 26, 2017

Study Registration Dates

• First Submitted: December 18, 2006
• First Submitted That Met QC Criteria: December 18, 2006
• First Posted (Estimate): December 20, 2006

Study Record Updates

• Last Update Posted (Actual): October 30, 2018
• Last Update Submitted That Met QC Criteria: October 1, 2018
• Last Verified: October 1, 2018

More Information

Terms related to this study

• Keywords: safety; open-label; long-term
• Additional Relevant MeSH Terms: Immune System Diseases; Autoimmune Diseases; Joint Diseases; Musculoskeletal Diseases; Rheumatic Diseases; Connective Tissue Diseases; Arthritis; Arthritis, Rheumatoid; Molecular Mechanisms of Pharmacological Action; Enzyme Inhibitors; Protein Kinase Inhibitors; Tofacitinib
• Other Study ID Numbers: A3921024; 2006-005035-19 (EudraCT Number)